JP2025513521A5 - - Google Patents

Info

Publication number
JP2025513521A5
JP2025513521A5 JP2024562265A JP2024562265A JP2025513521A5 JP 2025513521 A5 JP2025513521 A5 JP 2025513521A5 JP 2024562265 A JP2024562265 A JP 2024562265A JP 2024562265 A JP2024562265 A JP 2024562265A JP 2025513521 A5 JP2025513521 A5 JP 2025513521A5
Authority
JP
Japan
Prior art keywords
formula
fmoc
following
obtaining
carried out
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024562265A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025513521A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2023/019452 external-priority patent/WO2023205451A1/en
Publication of JP2025513521A publication Critical patent/JP2025513521A/ja
Publication of JP2025513521A5 publication Critical patent/JP2025513521A5/ja
Pending legal-status Critical Current

Links

JP2024562265A 2022-04-22 2023-04-21 治療薬を送達するための環状ペプチド Pending JP2025513521A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202263363450P 2022-04-22 2022-04-22
US63/363,450 2022-04-22
US202263354471P 2022-06-22 2022-06-22
US63/354,471 2022-06-22
US202263377754P 2022-09-30 2022-09-30
US63/377,754 2022-09-30
PCT/US2023/019452 WO2023205451A1 (en) 2022-04-22 2023-04-21 Cyclic peptides for delivering therapeutics

Publications (2)

Publication Number Publication Date
JP2025513521A JP2025513521A (ja) 2025-04-24
JP2025513521A5 true JP2025513521A5 (https=) 2026-04-28

Family

ID=86332269

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024562265A Pending JP2025513521A (ja) 2022-04-22 2023-04-21 治療薬を送達するための環状ペプチド

Country Status (6)

Country Link
US (1) US20250289851A1 (https=)
EP (1) EP4511385A1 (https=)
JP (1) JP2025513521A (https=)
CN (1) CN119156395A (https=)
CA (1) CA3249036A1 (https=)
WO (1) WO2023205451A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2024325879A1 (en) 2023-08-17 2026-03-12 Entrada Therapeutics, Inc. Intracellular targeting of oligonucleotides
WO2025038901A1 (en) 2023-08-17 2025-02-20 Entrada Therapeutics, Inc. Cyclic peptides for delivering therapeutics

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5506337A (en) 1985-03-15 1996-04-09 Antivirals Inc. Morpholino-subunit combinatorial library and method
US5217866A (en) 1985-03-15 1993-06-08 Anti-Gene Development Group Polynucleotide assay reagent and method
US5521063A (en) 1985-03-15 1996-05-28 Antivirals Inc. Polynucleotide reagent containing chiral subunits and methods of use
US5166315A (en) 1989-12-20 1992-11-24 Anti-Gene Development Group Sequence-specific binding polymers for duplex nucleic acids
US5235033A (en) 1985-03-15 1993-08-10 Anti-Gene Development Group Alpha-morpholino ribonucleoside derivatives and polymers thereof
US5185444A (en) 1985-03-15 1993-02-09 Anti-Gene Deveopment Group Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
NZ530101A (en) 2001-05-17 2007-01-26 Avi Biopharma Inc Methods for treating cancer by administering an oligomer antisense to c-myc together with a cancer chemotherapeutic agent
JP2005507660A (ja) 2001-10-16 2005-03-24 アビ バイオファーマ， インコーポレイテッド ｓｓＲＮＡウイルス感染の処置のためのアンチセンス抗ウイルス剤および方法
CA2553104A1 (en) 2004-01-23 2005-08-11 Avi Biopharma, Inc. Antisense oligomers and methods for inducing immune tolerance and immunosuppression
US7402574B2 (en) 2004-03-12 2008-07-22 Avi Biopharma, Inc. Antisense composition and method for treating cancer
US8357664B2 (en) 2004-10-26 2013-01-22 Avi Biopharma, Inc. Antisense antiviral compound and method for treating influenza viral infection
US8067571B2 (en) 2005-07-13 2011-11-29 Avi Biopharma, Inc. Antibacterial antisense oligonucleotide and method
WO2007030576A2 (en) 2005-09-08 2007-03-15 Avi Biopharma, Inc. Antisense antiviral compound and method for treating picornavirus infection
PL2735568T3 (pl) 2006-05-10 2018-02-28 Sarepta Therapeutics, Inc. Analogi oligonukleotydowe mające kationowe połączenia pomiędzy podjednostkami
WO2009005793A2 (en) 2007-06-29 2009-01-08 Avi Biopharma, Inc. Tissue specific peptide conjugates and methods
US20100016215A1 (en) 2007-06-29 2010-01-21 Avi Biopharma, Inc. Compound and method for treating myotonic dystrophy
US8076476B2 (en) 2007-11-15 2011-12-13 Avi Biopharma, Inc. Synthesis of morpholino oligomers using doubly protected guanine morpholino subunits
US8299206B2 (en) 2007-11-15 2012-10-30 Avi Biopharma, Inc. Method of synthesis of morpholino oligomers
BR122020021379B1 (pt) 2008-10-24 2021-05-11 Sarepta Therapeutics, Inc. oligômero morfolino fosforodiamidato, composição que compreende o mesmo e uso do dito oligômero para tratar distrofia muscular
US20100210989A1 (en) 2008-12-23 2010-08-19 Janet Lesley Macpherson Processing blood
ES2607603T3 (es) 2010-09-30 2017-04-03 Nippon Shinyaku Co., Ltd. Derivado de ácido morfolino nucleico
US9161948B2 (en) 2011-05-05 2015-10-20 Sarepta Therapeutics, Inc. Peptide oligonucleotide conjugates
JP6496549B2 (ja) 2011-11-30 2019-04-03 サレプタ セラピューティクス， インコーポレイテッド 脊髄性筋萎縮症における誘発されたエクソン包含
DK3015467T3 (da) 2013-05-24 2025-02-10 Ajinomoto Kk Morpholino-oligonukleotidfremstillingsfremgangsmåde
JP6807831B2 (ja) * 2014-05-21 2021-01-06 エントラーダ セラピューティクス，インコーポレイテッド 細胞膜透過性ペプチド、並びにこの作製方法及び使用方法
US11472824B2 (en) 2016-05-24 2022-10-18 Sarepta Therapeutics, Inc. Processes for preparing phosphorodiamidate morpholino oligomers
TW202500573A (zh) * 2016-11-22 2025-01-01 俄亥俄州立創新基金會 細胞穿透肽序列
EA201991450A1 (ru) 2017-09-22 2019-12-30 Сарепта Терапьютикс, Инк. Конъюгаты олигомеров для пропуска экзона при мышечной дистрофии
WO2019060862A1 (en) 2017-09-25 2019-03-28 Sarepta Therapeutics, Inc. METHODS FOR PREPARING MORPHOLINO PHOSPHORODIAMIDATE OLIGOMERS VIA FAST FLOW SYNTHESIS
WO2019165183A1 (en) * 2018-02-22 2019-08-29 Entrada Therapeutics, Inc. Compositions and methods for treating mitochondrial neurogastrointestinal encephalopathy
US10758629B2 (en) 2018-05-29 2020-09-01 Sarepta Therapeutics, Inc. Exon skipping oligomer conjugates for muscular dystrophy
US12012427B2 (en) 2019-10-31 2024-06-18 Indian Association For The Cultivation Of Science Synthesis of Fmoc-protected morpholino monomers and their use in the synthesis of morpholino oligomer
CN117120456A (zh) 2020-12-11 2023-11-24 卫材R&D管理有限公司 聚-吗啉代寡核苷酸缺口体
AU2022271873A1 (en) * 2021-05-10 2024-01-04 Entrada Therapeutics, Inc. Compositions and methods for intracellular therapeutics
WO2023081893A1 (en) * 2021-11-08 2023-05-11 Entrada Therapeutics, Inc. Intracellular targeting of oligonucleotides

Similar Documents

Publication Publication Date Title
CA3017926C (en) Methods for synthesizing .alpha.4.beta.7 peptide antagonists
EP3778621B1 (en) Peptide synthesis method
US8546530B2 (en) Process for the manufacture of persilylated peptides
DE69223266T2 (de) Peptidderivate und deren Verwendung
JP2025513521A5 (https=)
CN102112485B (zh) 乙酸格拉默(glatiramer acetate)的合成
JP6703669B2 (ja) リュープロレリンの製造方法
CN107001409A (zh) 疏水性肽的制造方法
CN108779150B (zh) 地加瑞克的制备方法及其中间体
JP2024501120A (ja) 化学合成のための組成物及び方法
JPH03504496A (ja) 水素結合の共有結合置換により安定化されたポリペプチド
EP3713950A1 (en) Method for preparing peptides
JP6788376B2 (ja) アスパラギン酸残基を含むペプチドの製造方法
CN112566895B (zh) 用于肽合成的可切割接头
WO2023021173A1 (en) Process for the preparation of pegylated adrenomedullin, its intermediates and use thereof
US5942601A (en) Peptide synthesis with sulfonyl protecting groups
JP2005325109A (ja) 環状ペプチド中のジスルフィド結合の形成方法
WO2000068252A1 (en) Methods and compositions for controlled polypeptide synthesis
JPH04221394A (ja) ペプチド脂質
JPH04305597A (ja) ペプチド含有ポリエチレングリコール誘導体
JP5097104B2 (ja) 新規イソジペプチド
WO2006105199A2 (en) Compositions and methods for synthesis of peptide and related conjugate
HK40105911A (zh) 包含磷酰胆碱缀合物的肽及其合成方法
JP2006520743A (ja) 二環式ヘキサペプチド、ネパデュタントの製造方法
JPH0680691A (ja) シスチン含有ペプチドの製造方法